Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Routine Clinical Liquid Biopsy Testing for Solid Tumors Delivers the Promise of Minimally Invasive Detection of Genomic Variants With a Faster Turnaround Time.

JCO precision oncology - 1 Mar 2025

Wang Peng, Yang Richard Kenneth, Jelloul Fatima Zahra, Luthra Rajyalakshmi, Routbort Mark J, Chen Hui, Loghavi Sanam, Ok Chi Young, Kanagal-Shamanna Rashmi, Roy-Chowdhuri Sinchita, Medeiros L Jeffrey, Patel Keyur P

Abstract excerpt

PURPOSE: A 70-gene liquid biopsy (LB) panel (LBP-70) was implemented at our institution to identify genetic alterations in the plasma of patients with solid tumors. We report the clinical utility of LBP-70 in a retrospective study of 1,243 consecutively tested patients. MATERIALS AND METHODS: Electronic medical records were reviewed for relevant clinicopathologic and radiologic information and preanalytical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRAF gene

Share to EGFR gene

Share to LBP gene

Share to Liquid Biopsy

Share to Mutation

Share to Neoplasms

Source

Identifiers

PMID: 40138600
DOI: 10.1200/PO.24.00299

Genes

LBP
BRAF
EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Routine Clinical Liquid Biopsy Testing for Solid Tumors Delivers the Promise of Minimally Invasive Detection of Genomic Variants With a Faster Turnaround Time.PMID 40138600Read ↗

Incidental pathogenic germline alterations detected through liquid biopsy in patients with solid tumors: prevalence, clinical utility and implications.Semantic proximity Read ↗

Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With Cancer: A Narrative Review.Semantic proximity Read ↗

Implementation of a 1021-gene liquid biopsy assay for real-world tumor genomic profiling in oncology practice.Semantic proximity Read ↗

Liquid biopsies across the cancer care continuum.Semantic proximity Read ↗

Liquid Biopsy: Approaches to Dynamic Genotyping in CancerSemantic proximity Read ↗

Liquid biopsies: genotyping circulating tumor DNA.Semantic proximity Read ↗

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors.Semantic proximity Read ↗

Analytical and Clinical Validation of an Amplicon-based Next Generation Sequencing Assay for Ultrasensitive Detection of Circulating Tumor DNASemantic proximity Read ↗

Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNASemantic proximity Read ↗

Analytical and clinical validation of an amplicon-based next generation sequencing assay for ultrasensitive detection of circulating tumor DNASemantic proximity Read ↗

Identification of circulating tumour DNA (ctDNA) from the liquid biopsy results: Findings from an observational cohort studySemantic proximity Read ↗

Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.